Avoro Capital

Avoro Capital Advisors is a New York-based global life sciences investment firm that focuses on supporting emerging biotechnology companies. Established in 2010, the firm specializes in making long-term, early-stage investments in healthcare companies, particularly within the biotechnology subsector. Avoro Capital provides investment advice and management to privately placed investment funds, as well as advisory services for separately managed accounts. The firm aims to achieve superior investment returns by investing primarily in equity and equity-related securities of privately-held companies in the life sciences sector.

Behzad Aghazadeh Ph.D

Managing Partner and Portfolio Manager

Matthew Canver

Director

Mark Chin

Investment Partner - Avoro Ventures

Uya Chuluunbaatar

Investment Partner - Avoro Ventures

Samir Devalaraja

Analyst

Max Isberg

Analyst

Andrew Washkowitz

Director

12 past transactions

Aadi Bioscience

Post in 2025
Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Aadi Bioscience

Post in 2024
Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Ottimo Pharma

Series A in 2024
Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Krystal Biotech

Post in 2023
Krystal Biotech, Inc. is a biopharmaceutical company based in Pittsburgh, Pennsylvania, specializing in gene therapy for patients with rare skin diseases. Founded in 2015, the company develops innovative treatments using its proprietary STAR-D gene therapy platform, which targets dermatological conditions caused by genetic mutations. Its lead candidate, beremagene geperpavec (B-VEC), is in clinical development for dystrophic epidermolysis bullosa, having completed Phase I/II studies. Krystal Biotech is also advancing other product candidates, including KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, and KB301 and KB104, which are in preclinical stages for aesthetic skin conditions and Netherton Syndrome, respectively. Additionally, the company is exploring treatments for chronic skin diseases through its discovery-stage candidate KB5xx. Krystal Biotech aims to enhance the quality of life for patients suffering from debilitating skin disorders with its gene therapy solutions.

Aadi Bioscience

Post in 2022
Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Kymera Therapeutics

Post in 2022
Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Aadi Bioscience

Private Equity Round in 2021
Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Scribe Therapeutics

Series B in 2021
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapies utilizing engineered CRISPR technologies to address genetic disorders. Founded in 2018 and based in Berkeley, California, Scribe Therapeutics is known for its proprietary X-Editing (XE) molecules, which are advanced CRISPR enzymes designed to enhance efficacy, specificity, and deliverability compared to existing genome editing methods. The company's platform aims to overcome the limitations of current technologies by creating custom-engineered enzymes and delivery systems that facilitate precise genetic modifications. Scribe Therapeutics is committed to establishing CRISPR-based therapies as a new standard of clinical care, with the potential to significantly impact the treatment landscape for a variety of diseases, including those related to immuno-oncology, degenerative disorders, and enzyme replacement therapy.

Monte Rosa Therapeutics

Series C in 2021
Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

PMV Pharmaceuticals

Series D in 2020
PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Mersana Therapeutics

Post in 2020
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Avadel Pharmaceuticals

Post in 2020
Avadel Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing differentiated drug products. It operates internationally with headquarters in Dublin and a presence in St. Louis and Lyon. The portfolio centers on urology, central nervous system/sleep, and hospital products, including LUMRYZ, an extended-release formulation of sodium oxybate for narcolepsy-related cataplexy and excessive daytime sleepiness in adults. The company markets three sterile injectable medicines for hospital use: Akovaz for hypotension during anesthesia, Bloxiverz for reversal of non-depolarizing neuromuscular blocking agents after surgery, and Vazculep for treatment of hypotension. Avadel pursues new product development through formulation innovation and partnerships to improve patient adherence and outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.